ArticleiGIE : innovation, investigation and insights2024
Expanding the boundaries of EUS: EUS-guided fiducial placement and fine-needle biopsy in oligometastatic disease of the adrenal gland.
Article in iGIE : innovation, investigation and insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation therapy, including Intensity Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT), is a crucial treatment for various malignancies, though side effects often arise from radiation exposure to healthy tissues. Fiducial markers are used in SBRT to optimize tumor targeting and minimize damage to surrounding tissues. Traditionally, fiducials are placed surgically or percutaneously, but EUS offers a safer, less invasive, and potentially cost-effective alternative. While fiducial placement within the pancreas has been well-studied, there are limited data on EUS-guided fiducial marker placement in non-GI organs, particularly the adrenal glands. Methods: This retrospective case series evaluated EUS-guided fiducial marker placement in the left adrenal gland in 6 patients from 2020 to 2023. Patients were selected following multidisciplinary tumor board discussions, and all procedures were performed using a 22-gauge Menghini-tip needle under EUS guidance. Data were collected on patient demographics, tumor characteristics, technical success, and clinical outcomes following fiducial placement. Results: The procedure was technically successful in all patients, with no reported adverse events. Four fiducials were placed in each patient, aiding SBRT planning. Five patients proceeded with SBRT, and 80% achieved a complete local response on radiological follow-up. No significant fiducial migration was noted. The findings suggest that EUS-guided fiducial placement for adrenal tumors is safe and effective. Conclusion: This is the first case series demonstrating the safety and technical success of EUS-guided fiducial placement in the adrenal gland. This technique offers an alternative to more invasive approaches, facilitating precision radiotherapy for adrenal metastases, and highlights the expanding role of interventional endoscopists in oncology care. Further prospective studies are needed to validate these findings and expand their clinical application.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.